organoids

Sales & Marketing

Demyelinating diseases, including multiple sclerosis (MS) and Charcot-Marie-Tooth (CMT) disease, present a substantial and escalating burden.

R&D

Organoid-based approaches may become an integral part of neurological safety testing, offering a clearer view of risk.

R&D

While support for reducing animal use has never been stronger, the path to broad adoption is steep and complex.

News

The UK government has set out an ambitious plan to phase out animal testing in scientific studies within five years.

R&D

On the emergence of brain organoids and the advent of automation, the latter being essential for high-throughput approaches drug development demands.

R&D

Adityo Prakash, founder and CEO of Verseon, discusses small datasets, real-world scenarios, and organoids.